RTP Mobile Logo
Expert Second Opinion: Investigators Discuss Available Clinical Research in the Care of Patients with Non-Small Cell Lung Cancer and Validated Targets Beyond EGFR (Webinar Video Proceedings)
Released November 2021

Featuring perspectives from Drs Ross Camidge, Alexander Drilon and Justin Gainor. Published November 5, 2021. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

    LEARNING OBJECTIVES

    • Recognize the spectrum of oncogenic alterations, beyond those associated with EGFR, identifiable in patients with non-small cell lung cancer (NSCLC), and determine how they might predict response to novel targeted therapies.
    • Appraise the efficacy and safety of approved and investigational ALK inhibitors, and determine how these agents can be integrated into the protocol and nonresearch care of patients with NSCLC with ALK rearrangements.
    • Consider the mechanism of action of, available data with and FDA approval of entrectinib for patients with NSCLC with ROS1 alterations, and discern how this agent can be appropriately and safely integrated into routine clinical care.
    • Recall the FDA approvals of selpercatinib and pralsetinib for patients with RET-driven metastatic NSCLC, and evaluate how these agents should be appropriately and safely integrated into clinical practice.
    • Evaluate available clinical trial findings supporting the FDA approvals of capmatinib and tepotinib for metastatic NSCLC with MET exon 14 skipping mutations, and identify patients who might benefit from these agents.
    • Appreciate the frequency of KRAS G12C mutations in patients with NSCLC, and evaluate the mechanism of action and potential role of novel therapies targeting this genetic alteration.
    • Assess ongoing clinical research evaluating novel agents and treatment strategies under development for the management of NSCLC with actionable mutations beyond EGFR, and counsel patients regarding the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/WCLC2021/NSCLCTargeted/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/WCLC2021/NSCLCTargeted/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/WCLC2021/NSCLCTargeted/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/WCLC2021/NSCLCTargeted.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    D Ross Camidge, MD, PhD
    Professor of Medicine/Oncology
    Joyce Zeff Chair in Lung Cancer Research
    University of Colorado, Anschutz Medical Campus
    Denver, Colorado

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, GlaxoSmithKline, Helssin Healthcare SA, Janssen Biotech Inc, Lilly, Mersana Therapeutics, OnKure, Pfizer Inc, Qilu Pharmaceutical Co Ltd, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Bio-Thera Solutions; ILD Adjudication Committee: Daiichi Sankyo Inc; Scientific Advisory Board: Amgen Inc, Anchiano Therapeutics, Apollomics Inc, Elevation Oncology, Kestrel Pharmaceuticals, Nuvalent.

    Alexander E Drilon, MD
    Chief, Early Drug Development Service
    Associate Attending Physician
    Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Accommodations: Boehringer Ingelheim Pharmaceuticals Inc, Merck, Merus BV, Puma Biotechnology Inc; Associated Research Paid to Institution: Exelixis Inc, GlaxoSmithKline, Pfizer Inc, PharmaMar, Taiho Oncology Inc, Teva Oncology; Consulting Agreements: AbbVie Inc, ArcherDX Inc, AstraZeneca Pharmaceuticals LP, AXIS, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BerGenBio ASA, Blueprint Medicines, Chugai Pharmaceutical Co Ltd, Elevation Oncology, EMD Serono Inc, EPG Health, Exelixis Inc, Genentech, a member of the Roche Group, Harborside, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Ignyta Inc, Liberum, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Medendi Inc, Merus BV, Monopteros Therapeutics, MORE Health Inc, Novartis, Nuvalent, Pfizer Inc, Remedica Ltd, Repare Therapeutics, Takeda Pharmaceuticals USA Inc, TP Therapeutics Inc, Tyra Biosciences, Verastem Inc; Contracted Research: Foundation Medicine; Royalties: Wolters Kluwer.

    Justin F Gainor, MD
    Director, Center for Thoracic Cancers at Massachusetts General Hospital
    Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies
    Associate Professor of Medicine, Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by educational grants from Genentech, a member of the Roche Group, and Lilly.

    Release date: November 2021
    Expiration date: November 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Selection and Sequencing of Therapy for Patients with Non-Small Cell Lung Cancer (NSCLC) with an ALK Rearrangement

Optimal Use of Recently Approved RET Inhibitors in the Care of Patients with NSCLC with RET Alterations

Current and Future Directions in the Management of NSCLC with ROS1 Rearrangement

Rational Approaches to Targeting BRAF in Patients with NSCLC

Other Validated Targets Beyond EGFR (eg, MET, KRAS G12C)

Select Publications